Background {#Sec1}
==========

Several studies in childhood acute myeloid leukemia (AML) have been showing three prognostic cytogenetic group classification: favorable cytogenetics, that includes t(8;21), t(15;17) and inv(16), high-risk cytogenetics, that includes complex karyotypes, monosomy 7, monosomy 5, del(5)(q) or abnormalities in 3q, and intermediate risk: other changes \[[@CR1]\]. The subgroup that has -5/5q rearrangements is rare and comprises about 1−2.5 % of pediatric AML cases \[[@CR2]\]. This finding was recently confirmed by Johnston et *al*., which described cytogenetics data of 26 pediatric patients (1.2 %) with -5/5q abnormalities in a retrospective study, including 2240 children and observed that this cytogenetic subgroup presented a very poor outcome \[[@CR3]\]. Despite of a concise and comparative study in a large cohort of childhood AML, the low frequency of 5q- cases limit a full comprehension of the cytogenetic and clinical implications of this subgroup \[[@CR1], [@CR3], [@CR4]\]. Thus, to contribute to the understanding of this rare subgroup within childhood AML, we describe the clinical, G-banding and molecular cytogenetic data of a child with AML showing an uncommon deletion 5q22 in a new complex karyotype.

Case presentation {#Sec2}
=================

Case report {#Sec3}
-----------

A 10-year-old boy was admitted with a 4-months history of fever, generalized lymphadenopathies and weight loss. Physical examination revealed mucositis and gingival hyperplasia. The abdomen was painless with no palpable mass. Imaging examination revealed mediastinal widening. At admission, the hemoglobin was 7.2g/L, white blood cell count was 67.5x10^9^/L and platelet count was 275x10^9^/L. The peripheral blood smear showed 80 % of blast cells. Bone marrow was hypercellular with 94,6 % FAB-M1 myeloid blast cells, being 93,7 % of granulocytic progenitors (CD34^hi^; MPO^-/+(50\ %)^; CD117^hi^; HLA-DR^hi^; CD13^hi^; CD36^−^; CD11b^−^; CD16^−^; CD64^−^; CD35^−^; CD14^−^; IREM-; CD71^lo^; CD105^−^; CD33^-/+(50\ %)^; TdT^+^; CD7^-/+(5\ %)^; CD38^+^, CD2^+^; CD15^+^). The patient was initially classified for intermediate-risk arm, and treated on AML-BFM 2012 protocol \[[@CR5]\].

Morphological examination of the bone marrow on days 15 and 33 of induction chemotherapy revealed myeloid blast cells comprising \>25 % (M3 bone marrow evaluation) and M2 (- \>5 to 25 %), respectively. At the 42nd day from the beginning of the treatment, the blast cell percentage in the bone marrow was 21,6 %. The patient achieved a late complete remission (0.7 % blast cells, \< 5 % - M1) only on day 79 of treatment. Due to the persistence of blast cells after the second induction (42nd day from the beginning of the treatment), the patient was stratified to high-risk arm, and was submitted to allogeneic stem cell transplantation, as recommend by the protocol \[[@CR5]\]. This procedure was well tolerated and the patient is in continuous complete remission for eight months now and twelve months since initial diagnosis. This study was approved by the Ethics Committee of the Brazilian National Cancer Institute (CEP \#088/07).

Methods and results {#Sec4}
-------------------

G-banding studies revealed a karyotype 46,XY,der(2)?t(2;15),del(5), der(14)?add(14)(q23) in 15 of 20 metaphases analyzed (Figs. [1a, b and c](#Fig1){ref-type="fig"}). Several molecular approaches were performed to discover this complex karyotype. FISH was performed using the LSI *EGR1* SpectrumOrange/D5S23 (5q31), D5S721 SpectrumGreen (5p15) probes (Vysis) and showed a heterozygous *EGR1* deletion in 10 metaphases analyzed and interphase nuclei analysis revealed the same pattern in 150 of 200 analyzed cells (Fig. [1d](#Fig1){ref-type="fig"}). Although FISH using LSI *IGH* break apart showed no split signal (Fig. [1e](#Fig1){ref-type="fig"}), the position of IGH normal signal suggested that there was a translocation between the chromosomes 2 and 14 (Fig. [1e](#Fig1){ref-type="fig"}). Whole Chromosome Painting (WCP) probes for chromosomes 2, 14 and 15 were also applied and the results revealed a translocation between chromosomes 2 and 14 and also between the other homolog of chromosome 2 and chromosome 15, therefore the karyotype had no normal chromosome 2 (Fig. [1f](#Fig1){ref-type="fig"}). Further, Multicolor Chromosome Banding (MCB) was performed for chromosomes 2, 5, 14 and 15, as previously reported \[[@CR6]\]. Overall, MCB characterized a complex chromosomal alteration between chromosomes 2, 14 and 15 (Fig. [1g](#Fig1){ref-type="fig"}). In order to define all the breakpoints involved in this complex translocation, mainly 5q-, it was necessary to apply several Bacterial Artificial Chromosome (BAC) probes (Table [1](#Tab1){ref-type="table"}). The final karyotype was characterized as: 46,XY,t(2;14)(q23.1;q32.2),t(2:15)(p22.3;q21.1),del(5)(q22-qter). The karyotype was described according to the International System for Human Cytogenetic Nomenclature \[[@CR7]\].Fig. 1**a**, **b**, and **c** show the final partial G-banding karyotype. **a** t(2;15)(p22.3;q21.1); **b** del(5)(q22); **c** t(2;14)(q23.1;q32.2). **d** FISH with LSI 5p15/5q31 (EGR1) showing a deletion of the red signal (5q31) in a metaphase and in nuclei interphase. **e** FISH with WCP for chromosome 2 (green), 14 (red) and 15 (yellow) shows translocation between chromosomes 2, 14 and 15 (R-DAPI image). **f** FISH-results characterizing the normal and derivative chromosomes 2, 5, 14 and 15 are summarized. In the first line results of MCB for chromosome 2 are depicted and show both derivatives 2 and derivative 14 and 15. The second line shows the normal chromosome 5 and a derivative of chromosome 5. The third line shows the normal chromosome 14 and the derivative chromosomes 2 and 14. The fourth line shows the normal chromosome 15 and the derivative chromosomes 2 and 15. Here, MCB probe sets for chromosomes 2, 5, 14 and 15 were used. According to FISH and MCB results, the karyotype was re-interpreted as 46,XY, t(2;14)(q23.1;q32.2), t(2:15)(p22.3;q21.1) and del(5)(q22-qter)Table 1Probes and BACs applied in the case to characterize the breakpoint in each chromosome involvedCytobandPosition \[hg19\]ProbeResults in derivative chromosomes2p24.3chr2: 16,014,784-16,140,647RP11-119F22Signal on der(15); no split signal2q23.3chr2: 26,967,697-27,136,688RP11-106G13Signal on der(15); no split signal2p23.2chr2: 29,415,640-29,447,593SPEC ALKSignal on der(15); no split signal2p22.3chr2:35,864,069-36,032,088RP11-119B15Signal on both der(2); no split signal2q22.3chr2:145,181,324-145,355,222RP11-64O2Signal split on der(2) and on der(14)2q23.3chr2:153,589,449-153,743,069RP11-58K7Signal on der(14); no split signal5q15chr5:93,905,245-93,906,381RP11-461G12Signal on der(5)5q15chr5:95,549,050-95,550,779RP11-254I22Signal on der(5)5q15chr5:97,013,251-97,014,385RP11-72K17Signal on der(5)5q21.1chr5:98,701,067-98,853,238RP11-102H6Signal on der(5)5q21.1chr5:100,241,673-100,434,269RP11-109H23Signal on der(5)5q21.3chr5:106,587,839-106,772,024CTD-2337D22Signal on der(5)5q22.2chr5:112,045,171-112,208,641RP11-107C15Signal deleted on der(5)5q22.2chr5:112,460,936-112,667,499RP11-467F22Signal deleted on der(5)5q22.3chr5:114,413,269-114,575,374RP11-115D4Signal deleted on der(5)5q23.1chr5:116,078,687-116,097,905RP11-249M12Signal deleted on der(5)5q23.2chr5:123,826,090-123,997,725RP11-689H7Signal deleted on der(5)5q23.3chr5:126,087,655-126,112,178RP11-434D11Signal deleted on der(5)5q23.3chr5:130,278,846-130,432,829RP11-114H7Signal deleted on der(5)5q31.1chr5:131,789,105-131,949,164RP11-729C24Signal deleted on der(5)5q31.1chr5:135,712,100-135,888,152RP11-114H21Signal deleted on der(5)5q31.2chr5:137,829,080-137,832,903LSI EGR1Signal deleted on der(5)5q35.3chr5:180,578,142-180,778,814D5S2907Signal deleted on der(5)14q32.2chr14:98,088,984-98,162,995RP11-76E12Signal on der(14); no split signal14q32.2chr14:100,070,893-100,092,077RP11-543C4Signal on der(2q); no split signal14q32.33Chr14:106,053,226- 106,518,932LSI IGHSignal on der(2q); no split signal15q15.1chr15:41,796,423-41,967,115RP11-380D11Signal on der(15); no split signal15q21.1chr15:45,625,708-45,826,511RP11-519G16Signal on der(15); no split signal15q21.1chr15:46,258,718-46,459,407RP11-315O8Signal on der(2), no split signal15q21.1chr15:48,509,039-48,663,778RP11-154J22Signal on der(2), no split signal15q21.1chr15:49,049,766-49,223,905RP11-485O10Signal on der(2);no split signal15q21.1chr15:49,896,865-50,081,728RP11-353B9Signal on der(2); no split signal15q21.2chr15:50,385,284-50,543,688RP11-416K5Signal on der(2); no split signal15q21.2chr15:50,586,357-50,763,569RP11-802B2Signal on der(2); no split signal15q21.3chr15:53,791,870-53,948,902RP11-232J12Signal on der(2); no split signal

Discussion {#Sec5}
----------

Abnormalities of chromosome 5 are a common finding in patients with hematological malignancies with poor outcome \[[@CR8]\]. The deletion of the long arm of chromosome 5 and monosomy of 5 has been described most frequently in Myelodysplastic Syndrome (MDS) cases. However, it has been already documented as a recurring finding in AML and it is associated with dismal outcome \[[@CR9]\]. 5q deletion has been shown a wide variety of breakpoints and it has been reported within complex karyotypes.

Johnston and coworkers described in a wide retrospective cohort of 2240 pediatric AML patients, that 5q deletion was also associated with poor outcome, in which to have more than three cytogenetic abnormalities showed worse outcomes than those with three or fewer cytogenetic abnormalities \[[@CR3]\]. On the other hand, it is important to remark that 7/26 patients, from the above-mentioned work were classified as harboring unbalanced rearrangements resulting in 5q loss, all of that without thoroughly refine the karyotype in the search for the presence of cryptic abnormalities, which may be particularly hard to detect in G-banding cytogenetics.

In the present work, the patient carries on the deletion of chromosome 5 within a complex karyotype and has lost a large portion from the long arm of one of the chromosomes 5. Initially, the FISH assay, with LSI probes, demonstrated the deletion of 5q31, but with FISH using several BAC probes (Table [1](#Tab1){ref-type="table"}) and MCB approaches, we could detect the breakpoint in 5q22 which is an uncommon finding in patients harboring 5q deletion suggested by LSI FISH analysis.

Volkert *et al*., suggested that the type of cytogenetic abnormality leading to loss of 5q may harbor important prognostic information. A wide series of MSD and AML adult patients were taken into account in this work. This study showed that the two main commonly deleted regions (CDR) have distinct prognostic value. The CDR1 (5q32) is present in patients with 5q- MDS and isolated 5q deletion, being associated with a good prognosis. The CDR2 (5q31) is present in aggressive MDS and high-risk AML, and has been associated to complex karyotypes and demonstrated a worse prognosis \[[@CR9]\].

Interestingly, our patient presented a loss of large portions from the long arm of one of the chromosome 5 that comprised 5q22 to 5qter, including both CDR regions. In this large portion lost in our patient, the literature includes *APC, EGR1, CTNNA1, DIAPH1, NPM1, GLRA1, RPS14, UBE2D2* genes whose disruption of expression may lead to defects in hematopoiesis in mice and other defects in core process to cell development. Lastly, these defects would lead to progression towards AML or 5q- MDS \[[@CR10]\].

Harrison *et al*., succeeded in establishing that patients with 5q abnormalities (11/729) has a Hazard Ratio =3.75 (1−14, *p* = 0.01) in relation to patients without these abnormalities, when studying the event free survival \[[@CR1]\]. However, it was impossible to find similar statistical results in the other survival outcomes (disease free survival and overall survival), possibly because of the small number of patients in this subgroup. Both COG protocols and United Kingdom Medical Research Council Treatment Trials AML 10 and 12 stratify these patients in the high-risk arm what makes them candidates to allogeneic bone marrow transplantation (BMT).

In another clinical study, Von Neuhoff *et al*., was unable to demonstrate the worst prognostic implication of aberrations in chromosome 5q (14/454) \[[@CR4]\]. Although, it is not possible to determine if this inability was also due to a small number of patients. Patients with these types of cytogenetic abnormalities are classified in AML-BFM 2012 protocols as an intermediate risk group, and are not primarily directed to allogeneic BMT. Our patient was treated under the above-mentioned protocol and, because of a late achievement of complete remission; he was posteriorly stratified to high-risk group and submitted to BMT. Thus, if this uncommon breakpoint in 5q22 within complex karyotype has a prognostic impact, more studies with a wide series of AML cases should be performed to confirm our cytogenetic data.

Conclusion {#Sec6}
==========

Here, we described a case presenting an uncommon deletion 5q22 associated with novel abnormalities involving both chromosomes 2, revealed by MCB and BAC probes, as defined: 46,XY,t(2;14)(q23;q32.2),t(2;15)(p23;q15),del(5)(q22-qter) in a child that showed a very poor clinical response to treatment. The knowledge of more complete descriptions of such cases harboring 5q- abnormalities, obtained through the application of molecular cytogenetic approaches, are necessary to precisely stratify the risk of this rare subgroup in childhood AML.

Consent {#Sec7}
=======

Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

AML

:   Acute myeloid leukemia

APC

:   Adenomatous Polyposis coli

BAC

:   Bacterial artificial chromosome

BMT

:   Bone marrow transplantation

CD

:   Cluster differentiation

COG

:   Children Oncology Group

CTNNA1

:   Catenin Alpha 1

DIAPH1

:   Diaphanous--Related Formin 1

EGR1

:   Early growth response 1

FISH

:   Fluorescence in situ hybridization

GLRA1

:   Glycine Receptor Alpha 1

HLA-DR

:   Human leukocyte antigen-D related

IGH

:   Immunoglobulin heavy

IREM

:   Immune receptor expressed by myeloid cells

LSI

:   Locus specific

MCB

:   Multicolor chromosome banding

MDS

:   Myelodisplastic Syndrome

MPO

:   Mieloperoxidase

NPM1

:   Nucleophosmin 1

RPS14

:   Ribosomal Protein S14

TdT

:   Terminal Deoxynucleotidyl Transferase

UBE2D2

:   Ubiquitin-Conjugating Enzyme E2D 2
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